The optimal use of steroids in paediatric acute lymphoblastic leukaemia: No easy answers

British Journal of Haematology

Volumn 149, Issue 5, 2010, Pages 638-652

  McNeer, Jennifer L ^a   Nachman, James B ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Acute lymphoblastic leukaemia; Avascular necrosis; Dexamethasone; Glucocorticoids; Prednisone

Indexed keywords

ASPARAGINASE; DEXAMETHASONE; DOXORUBICIN; GLUCOCORTICOID; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADRENAL SUPPRESSION; AMINOTRANSFERASE BLOOD LEVEL; AVASCULAR NECROSIS; BEHAVIOR DISORDER; BLOOD CLOTTING DISORDER; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG PENETRATION; DRUG PULSE THERAPY; DRUG RESPONSE; DRUG WITHDRAWAL; FRACTURE; HEPATOMEGALY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INFECTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER TOXICITY; MAINTENANCE THERAPY; MENTAL DISEASE; MYALGIA; MYCOSIS; MYOPATHY; NEUROTOXICITY; NEUTROPENIA; OSTEOPENIA; PANCREAS INSUFFICIENCY; PANCREATITIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SIDE EFFECT; TREATMENT OUTCOME; VIRUS INFECTION; WEIGHT GAIN;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; INFANT; INFANT, NEWBORN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PREDNISONE;

EID: 77952612955     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08192.x     Document Type: Review

References (56)

1. Arico, M., Boccalatte, M.F., Silvestri, D., Barisone, E., Messina, C., Chiesa, R., Santoro, N., Tamaro, P., Lippi, A., Gallisai, D., Basso, G., De Rossi, G. Associazione Italiana di Ematologia ed Oncologia Pediatrica 2003) Osteonecrosis: an emerging complication of intensive chemotherapy for childhood acute lymphoblastic leukemia. Haematologica, 88, 747 753. (Pubitemid 36890108)
2. Assouline-Dayan, Y., Chang, C., Greenspan, A., Shoenfeld, Y. Gershwin, M.E. (2002) Pathogenesis and natural history of osteonecrosis. Seminars in Arthritis and Rheumatism, 32, 94 124.
3. Balis, F.M., Lester, C.M., Chrousos, G.P., Heideman, R.L. Poplack, D.G. (1987) Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. Journal of Clinical Oncology, 5, 202 207.
4. Bertrand, Y., Suciu, S., Benoit, Y., Robert, A., Nelken, B., Uyttebroeck, A., Lutz, P., Ferster, A., Baruchel, A., Norton, L., Margueritte, G., Rohrlich, P., Munzer, M., Plantaz, D., Millot, F., Boutard, P., Sirvent, N., Hoyoux, C., Baila, L. Otten, J. (2008) Dexamethasone (DEX)(6mg/sm/d) and prednisolone (PRED)(60mg/sm/d) in induction therapy of childhood ALL are equally effective: results of the 2nd interim analysis of EORTC trial 58951. Blood (ASH Meeting Abstracts), 112, 8.
5. Bleyer, W.A., Sather, H.N., Nickerson, H.J., Coccia, P.F., Finklestein, J.Z., Miller, D.R., Littman, P.S., Lukens, J.N., Siegel, S.E. Hammond, G.D. (1991) Monthly pulses of vincristine and prednisone prevent bone marrow and testicular relapse in low-risk childhood acute lymphoblastic leukemia: a report of the CCG-161 study by the Children's Cancer Study Group. Journal of Clinical Oncology, 9, 1012 1021.
6. Borowitz, M.J., Devidas, M., Hunger, S.P., Bowman, W.P., Carroll, A.J., Carroll, W.L., Linda, S., Martin, P.L., Pullen, D.J., Viswanatha, D., Willman, C.L., Winick, N., Camitta, B.M. Children's Oncology Group 2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood, 111, 5477 5485.
7. Bostrom, B.C., Sensel, M.R., Sather, H.N., Gaynon, P.S., La, M.K., Johnston, K., Erdmann, G.R., Gold, S., Heerema, N.A., Hutchinson, R.J., Provisor, A.J., Trigg, M.E. Children's Cancer Group 2003) Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 101, 3809 3817.
8. Burger, B., Beier, R., Zimmermann, M., Beck, J.D., Reiter, A. Schrappe, M. (2005) Osteonecrosis: a treatment related toxicity in childhood acute lymphoblastic leukemia (ALL) - experiences from trial ALL-BFM 95. Pediatric Blood & Cancer, 44, 220 225.
9. Childhood ALL Collaborative Group 1996) Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children. Lancet, 347, 1783 1788.
10. Conter, V., Valsecchi, M.G., Silvestri, D., Campbell, M., Dibar, E., Magyarosy, E., Gadner, H., Stary, J., Benoit, Y., Zimmermann, M., Reiter, A., Riehm, H., Masera, G. Schrappe, M. (2007) Pulses of vincristine and dexamethasone in addition to intensive chemotherapy for children with intermediate-risk acute lymphoblastic leukaemia: a multicentre randomised trial. Lancet, 369, 123 131.
11. Conter, V., Bartram, C.R., Valsecchi, M.G., Schrauder, A., Panzer-Grumayer, R., Moricke, A., Arico, M., Zimmermann, M., Mann, G., De Rossi, G., Stanulla, M., Locatelli, F., Basso, G., Niggli, F., Barison, E., Henze, G., Ludwig, W.-D., Haas, O.A., Cazzaniga, G., Koehler, R., Silvestri, D., Bradtke, J., Parasole, R., Beier, R., van Dongen, J.J.M., Biondi, A. Schrappe, M. (2010) Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood, doi :.
12. De Moerloose, B., Suciu, S., Bertrand, Y., Mazingue, F., Robert, A., Uyttebroeck, A., Yacouben, K., Ferster, A., Margueritte, G., Lutz, P., Munzer, M., Sirvent, N., Norton, L., Boutard, P., Plantaz, D., Millot, F., Philippet, P., Baila, L., Benoit, Y. Otten, J. (2008) Improved outcome with pulses of vincristine and steroids in continuation therapy of children with average risk acute lymphoblastic leukemia (ALL) and non hodgkin lymphoma (NHL): final report of the EORTC randomised phase III trial 58951. Blood (ASH Meeting Abstracts), 112, 11.
13. Gaynon, P.S. Lustig, R.H. (1995) The use of glucocorticoids in acute lymphoblastic leukemia of childhood. Molecular, cellular, and clinical considerations. Journal of Pediatric Hematology/Oncology, 17, 1 12.
14. Gaynon, P.S., Bleyer, W.A., Steinherz, P.G., Finklestein, J.Z., Littman, P.S., Miller, D.R., Reaman, G.H., Sather, H.N. Hammond, G.D. (1988) Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of children's cancer study group study CCG-193P. The American Journal of Pediatric Hematology/Oncology, 10, 42 50.
15. Gaynon, P.S., Steinherz, P.G., Bleyer, W.A., Ablin, A.R., Albo, V.C., Finklestein, J.Z., Grossman, N.J., Novak, L.J., Pyesmany, A.F., Reaman, G.H., Chappell, R.J., Sather, H.N. Hammond, G.D. (1993) Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Children's Cancer Group study CCG-106. Journal of Clinical Oncology, 11, 2234 2242.
16. Gaynon, P.S., Trigg, M.E., Heerema, N.A., Sensel, M.G., Sather, H.N., Hammond, G.D. Bleyer, W.A. (2000) Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia, 14, 2223 2233.
17. Henze, G., Langermann, H.J., Bramswig, J., Breu, H., Gadner, H., Schellong, G., Welte, K. Riehm, H. (1981) The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl). Klinische Padiatrie, 193, 145 154.
18. Hurwitz, C.A., Silverman, L.B., Schorin, M.A., Clavell, L.A., Dalton, V.K., Glick, K.M., Gelber, R.D. Sallan, S.E. (2000) Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia. Cancer, 88, 1964 1969.
19. Hutchinson, R.J., Gaynon, P.S., Sather, H., Bertolone, S.J., Cooper, H.A., Tannous, R., Wells, L.M., Heerema, N.A., Sailer, S., Trigg, M.E. Children's Cancer Group/Children's Oncology Group 2003) Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group trial 1881. Journal of Clinical Oncology, 21, 1790 1797.
20. Igarashi, S., Manabe, A., Ohara, A., Kumagai, M., Saito, T., Okimoto, Y., Kamijo, T., Isoyama, K., Kajiwara, M., Sotomatsu, M., Sugita, K., Sugita, K., Maeda, M., Yabe, H., Kinoshita, A., Kaneko, T., Hayashi, Y., Ikuta, K., Hanada, R. Tsuchida, M. (2005) No advantage of dexamethasone over prednisolone for the outcome of standard- and intermediate-risk childhood acute lymphoblastic leukemia in the Tokyo Children's Cancer Study Group L95-14 protocol. Journal of Clinical Oncology, 23, 6489 6498.
21. Ito, C., Evans, W.E., McNinch, L., Coustan-Smith, E., Mahmoud, H., Pui, C.H. Campana, D. (1996) Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Journal of Clinical Oncology, 14, 2370 2376. (Pubitemid 26264890)
22. Jones, B., Freeman, A.I., Shuster, J.J., Jacquillat, C., Weil, M., Pochedly, C., Sinks, L., Chevalier, L., Maurer, H.M., Koch, K., Falkson, G., Patterson, R., Seligman, B., Sartorius, J., Kung, F., Haurani, F., Stuart, M., Burgert, E.O., Ruymann, F., Sawitsky, A., Forman, E., Pluess, H., Truman, J., Hakami, N., Glidewell, O., Glicksman, A.S. Holland, J.F. (1991) Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia. Medical and Pediatric Oncology, 19, 269 275.
23. Kadan-Lottick, N.S., Brouwers, P., Breiger, D., Kaleita, T., Dziura, J., Liu, H., Chen, L., Nicoletti, M., Stork, L., Bostrom, B. Neglia, J.P. (2009) A comparison of neurocognitive functioning in children previously randomised to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia. Blood, 114, 1746 1752.
24. Kaspers, G.J., Veerman, A.J., Popp-Snijders, C., Lomecky, M., Van Zantwijk, C.H., Swinkels, L.M., Van Wering, E.R. Pieters, R. (1996) Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. Medical and Pediatric Oncology, 27, 114 121.
25. Kerachian, M.A., Seguin, C. Harvey, E.J. (2009) Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. The Journal of Steroid Biochemistry and Molecular Biology, 114, 121 128.
26. Lange, B.J., Bostrom, B.C., Cherlow, J.M., Sensel, M.G., La, M.K., Rackoff, W., Heerema, N.A., Wimmer, R.S., Trigg, M.E., Sather, H.N. Children's Cancer Group 2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood, 99, 825 833.
27. Matloub, Y., Bostrom, B.C., Hunger, S.P., Angiolillo, A.L., Cole, C., Thomson, B., Devidas, M., Heerema, N.A., La, M.K., Buckley, P.J., Carroll, W.L., Winick, N., Sather, H., Nachman, J.B. Gaynon, P.S. (2008) Escalating dose intravenous methotrexate without leucovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): Children's Oncology Group study 1991. Blood (ASH Meeting Abstracts), 112, 9.
28. Mattano, Jr., L.A., Sather, H.N., Trigg, M.E. Nachman, J.B. (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the children's cancer group. Journal of Clinical Oncology, 18, 3262 3272.
29. Mattano, Jr., L.A., Nachman, J.B., Devidas, M., Winick, N., Raetz, E., Carroll, W.L., Whitlock, J.A., Hunger, S.P. Larsen, E.C. (2008) Increased incidence of osteonecrosis (ON) with a dexamethasone (DEX) induction for high risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group (COG). Blood (ASH Meeting Abstracts), 112, 898.
30. Mitchell, C.D., Richards, S.M., Kinsey, S.E., Lilleyman, J., Vora, A., Eden, T.O. Medical Research Council Childhood Leukaemia Working Party 2005) Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK medical research council ALL97 randomised trial. British Journal of Haematology, 129, 734 745.
31. Moricke, A., Zimmermann, M., Schrauder, A., Stanulla, M., Schmid, H., Fengler, R., Fruhwald, M., Mann, G. Schrappe, M. (2008) No influence on the incidence of osteonecroses when dexamethasone replaces prednisone during induction treatment for childhood ALL: results of trial ALL-BFM 2000. Blood (ASH Meeting Abstracts), 112, 899.
32. Moricke, A., Zimmermann, M., Reiter, A., Henze, G., Schrauder, A., Gadner, H., Ludwig, W.-D., Ritter, J., Harbott, J., Mann, G., Klingebiel, T., Zintl, F., Niemeyer, C., Kremens, B., Niggli, F., Niethammer, D., Welte, K., Stanulla, M., Odenwald, E., Riehm, H. Schrappe, M. (2010) Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia, 24, 265 284.
33. Motomura, G., Yamamoto, T., Irisa, T., Miyanishi, K., Nishida, K. Iwamoto, Y. (2008) Dose effects of corticosteroids on the development of osteonecrosis in rabbits. The Journal of Rheumatology, 35, 2395 2399.
34. Nachman, J., Sather, H.N., Cherlow, J.M., Sensel, M.G., Gaynon, P.S., Lukens, J.N., Wolff, L. Trigg, M.E. (1998a) Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. Journal of Clinical Oncology, 16, 920 930.
35. Nachman, J.B., Sather, H.N., Sensel, M.G., Trigg, M.E., Cherlow, J.M., Lukens, J.N., Wolff, L., Uckun, F.M. Gaynon, P.S. (1998b) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. The New England Journal of Medicine, 338, 1663 1671.
36. Norton, L. Simon, R. (1986) The Norton-Simon hypothesis revisited. Cancer Treatment Reports, 70, 163 169.
37. Reiter, A., Schrappe, M., Ludwig, W.-D., Hiddemann, W., Sauter, S., Henze, G., Zimmermann, M., Lampert, F., Havers, W., Niethammer, D., Odenwald, E., Ritter, J., Mann, G., Welte, K., Gadner, H. Riehm, H. (1994) Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood, 84, 3122 3133.
38. Renner, K., Ausserlechner, M.J. Kofler, R. (2003) A conceptual view on glucocorticoid-induced apoptosis, cell cycle arrest and glucocorticoid resistance in lymphoblastic leukemia. Current Molecular Medicine, 3, 707 717.
39. Riehm, H., Reiter, A., Schrappe, M., Berthold, F., Dopfer, R., Gerein, V., Ludwig, R., Ritter, J., Stollmann, B. Henze, G. (1987) Corticosteroid- dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83). Klinische Padiatrie, 199, 151 160.
40. Schrappe, M., Reiter, A., Zimmermann, M., Harbott, J., Ludwig, W.-D., Henze, G., Gadner, H., Odenwald, E. Riehm, H. (2000) Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia, 14, 2205 2222.
41. Schrappe, M., Zimmerman, M., Moricke, A., Mann, G., Valsecchi, M.G., Bartram, C.R., Biondi, A., Panzer-Grumayer, R., Schrauder, A., Locatelli, F., Reiter, A., Basso, G., Niggli, F., Arico, M. Conter, V. (2008) Dexamethasone in induction can eliminate one-third of all relapses in childhood acute lymphoblastic leukemia (ALL): results of an international randomised trial in 3655 patients (trial AIEOP-BFM ALL 2000). Blood (ASH Meeting Abstracts), 112, 7.
42. Seibel, N.L., Steinherz, P.G., Sather, H.N., Nachman, J.B., Delaat, C., Ettinger, L.J., Freyer, D.R., Mattano, Jr., L.A., Hastings, C.A., Rubin, C.M., Bertolone, K., Franklin, J.L., Heerema, N.A., Mitchell, T.L., Pyesmany, A.F., La, M.K., Edens, C. Gaynon, P.S. (2008) Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 111, 2548 2555.
43. Silverman, L.B., Gelber, R.D., Dalton, V.K., Asselin, B.L., Barr, R.D., Clavell, L.A., Hurwitz, C.A., Moghrabi, A., Samson, Y., Schorin, M.A., Arkin, S., Declerck, L., Cohen, H.J. Sallan, S.E. (2001) Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium protocol 91-01. Blood, 97, 1211 1218.
44. Strauss, A.J., Su, J.T., Dalton, V.M., Gelber, R.D., Sallan, S.E. Silverman, L.B. (2001) Bony morbidity in children treated for acute lymphoblastic leukemia. Journal of Clinical Oncology, 19, 3066 3072.
45. Styczynski, J., Wysocki, M., Balwierz, W., Rokicka-Milewska, R., Matysiak, M., Balcerska, A., Kowalczyk, A., Wachowiak, J., Sonta-Jakimczyk, D. Chybicka, A. (2002) In vitro comparative antileukemic activity of various glucocorticoids in childhood acute leukemia. Neoplasma, 49, 178 183.
46. Te Poele, E.M., de Bont, E.S., Marike Boezen, H., Revesz, T., Bokkerink, J.P., Beishuizen, A., Nijhuis, I.J., Oude Nijhuis, C.S., Veerman, A.J. Kamps, W.A. (2007) Dexamethasone in the maintenance phase of acute lymphoblastic leukaemia treatment: is the risk of lethal infections too high? European Journal of Cancer, 43, 2532 2536.
47. Tubergen, D.G., Gilchrist, G.S., O'Brien, R.T., Coccia, P.F., Sather, H.N., Waskerwitz, M.J. Hammond, G.D. (1993) Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. Journal of Clinical Oncology, 11, 527 537.
48. Veerman, A.J., Hahlen, K., Kamps, W.A., Van Leeuwen, E.F., De Vaan, G.A., Solbu, G., Suciu, S., Van Wering, E.R. Van der Does-Van der Berg, A. (1996) High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. Journal of Clinical Oncology, 14, 911 918.
49. Veerman, A.J., Kamps, W.A., van den Berg, H., van den Berg, E., Bokkerink, J.P., Bruin, M.C., van den Heuvel-Eibrink, M.M., Korbijn, C.M., Korthof, E.T., van der Pal, K., Stijnen, T., van Weel Sipman, M.H., van Weerden, J.F., van Wering, E.R., van der Does-van den Berg, A. Dutch Childhood Oncology Group 2009) Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004). The Lancet Oncology, 10, 957 966.
50. Vora, A., Wade, R., Mitchell, C., Goulden, N. Richards, S. (2008) Incidence and outcome of osteonecrosis in children and young adults with acute lymphoblastic leukaemia treated on a dexamethasone containing protocol: results of the Medical Research Council UK trial ALL 2003. Blood (ASH Meeting Abstracts), 112, 910.
51. Vrooman, L.M., Neuberg, D.S., Stevenson, K.E., Supko, J.G., Sallan, S.E. Silverman, L.B. (2009) Dexamethasone and individualized asparaginase dosing are each associated with superior event-free survival in childhood acute lymphoblastic leukemia: results from DFCI-ALL Consortium protocol 00-01. Blood (ASH Meeting Abstracts), 114, 321.
52. Waber, D.P., Carpentieri, S.C., Klar, N., Silverman, L.B., Schwenn, M., Hurwitz, C.A., Mullenix, P.J., Tarbell, N.J. Sallan, S.E. (2000) Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone. Journal of Pediatric Hematology/Oncology, 22, 206 213.
53. Werner, A., Jager, M., Schmitz, H. Krauspe, R. (2003) Joint preserving surgery for osteonecrosis and osteochondral defects after chemotherapy in childhood. Klinische Padiatrie, 215, 332 337.
54. Winick, N., Martin, P.L., Devidas, M., Shuster, J., Borowitz, M.J., Bowman, P., Larsen, E., Pullen, J., Hunger, S.P., Carroll, W.L. Camitta, B.M. (2007) Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): POG 9904/9905: a Children's Oncology Group study (COG). Blood (ASH Meeting Abstracts), 110, 583.
55. Yang, L., Boyd, K., Kaste, S.C., Kamdem Kamdem, L., Rahija, R.J. Relling, M.V. (2009) A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. Journal of Orthopaedic Research, 27, 169 175.
56. Zalavras, C., Shah, S., Birnbaum, M.J. Frenkel, B. (2003) Role of apoptosis in glucocorticoid-induced osteoporosis and osteonecrosis. Critical Reviews in Eukaryotic Gene Expression, 13, 221 235.